tislelizumab
beigene,novartis
rationale-306: #tislelizumab significantly extended median overall survival in advanced #essc #esophagealcancer #wcgic2022 #esmo2022 #cancer 
Medical Advisers Group // medical infographics agency // https://t.co/HjnzbbHDB9